A Phase 1, Observer-blind, Randomized, Placebo-Controlled Study to Evaluate Reactogenicity, Safety and Immune Response of an HSV-targeted Immunotherapy in HSV-2 Seronegative Japanese Participants Aged 18-40 Years
Latest Information Update: 06 May 2024
At a glance
- Drugs Herpes simplex virus targeted immunotherapy (Primary)
- Indications Herpes simplex virus infections
- Focus Adverse reactions
- Acronyms TH HSV REC-004
- Sponsors GSK
Most Recent Events
- 29 Apr 2024 Status changed from active, no longer recruiting to completed.
- 23 Nov 2023 Planned End Date changed from 9 May 2024 to 3 May 2024.
- 23 Nov 2023 Planned primary completion date changed from 27 Nov 2023 to 29 Nov 2023.